Drug Type Small molecule drug |
Synonyms Brimonidine/loteprednol etabonate, Loteprednol Etabonate/Brimonidine |
Target |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS Registry70359-46-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Xerophthalmia | Phase 3 | - | - | |
Dry Eye Syndromes | Phase 2 | US | 03 Dec 2018 |